A meta-analysis has been published that reviewed the clinical studies that looked at the use of a multivitamin in people with HIV. There was enough data of people not yet on antiretrovirals and we showed a significant effect on how fast AIDS develops after HIV infection (the progression rate).
CONCLUSIONS: MNS significantly and substantially slows disease progression in HIV+ adults not on ARV, and possibly reduces mortality. Micronutrient supplements are effective in reducing progression with a posterior probability of 97.9%. Considering MNS low cost and lack of adverse effects, MNS should be standard of care for HIV+ adults not yet on ARV.
There was also evidence that it could reduce the risk of dying (mortality). There weren’t enough studies to assess the effect of a multi among those on ARV, though these studies are also discussed.
The first author of the study was NYBC’s George Carter, who was working as part of an NIH grant with colleagues at Mount Sinai in New York.